HomeInsightsStock Comparison

Kopran Ltd vs Venmax Drugs Pharmaceuticals Ltd Stock Comparison

Kopran Ltd vs Venmax Drugs Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jul 18, 2025

Key Highlights

  • The Latest Trading Price of Kopran Ltd is ₹ 179.05 as of 18 Jul 10:48.
  • The P/E Ratio of Kopran Ltd changed from 5.2 on March 2020 to 24.5 on March 2024 . This represents a CAGR of 36.34% over 5 yearsThe P/E Ratio of Venmax Drugs & Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Kopran Ltd changed from ₹ 109.65 crore on March 2020 to ₹ 1245 crore on March 2024 . This represents a CAGR of 62.59% over 5 yearsThe Market Cap of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Kopran Ltd for the Mar '25 is ₹ 175.62 crore as compare to the Dec '24 revenue of ₹ 166.41 crore. This represent the growth of 5.53% The revenue of Venmax Drugs & Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Kopran Ltd for the Mar '25 is ₹ 20.35 crore as compare to the Dec '24 ebitda of ₹ 20.01 crore. This represent the growth of 1.7% The ebitda of Venmax Drugs & Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Kopran Ltd changed from ₹ 2.77 crore to ₹ 9.68 crore over 8 quarters. This represents a CAGR of 86.94% The net profit of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 41.75 % on March 2024 . This represents a CAGR of -6.78% over 4 yearsThe Dividend Payout of Venmax Drugs & Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Kopran Ltd

  • Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises.
  • The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment.
  • It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin.
  • Kopran also makes penicillin-G acylase, an enzyme made through fermentation.
  • It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities.

About Venmax Drugs & Pharmaceuticals Ltd

  • Venmax Drugs & Pharmaceuticals Limited, (VDPL) was initially incorporated as Private Limited Company under the name and style of 'Yenkay Medico Private Limited', on 28 September, 1998.
  • The Company thereafter changed its name to 'Yenkey Drugs & Pharmaceuticals Private Limited' on 18 January, 1995.
  • It became a Public Limited Company on February 3, 1995 with 'Yenkey Drugs & Pharmaceuticals Limited'.
  • Finally, the Company changed its name to 'Venmax Drugs & Pharmaceuticals Limited' on April 13, 2009. For the past six months, Company focused on establishing chain of Medical Stores with a brand name as 'Ananya Pharma' under the Venmax Drugs & Pharma Limited, with the backing support of Formulations plant (Suzichem Labs).
  • Initially, the Company engaged in the business of pharmaceutical products, drug intermediaries & API's etc.

Kopran Ltd News Hub

News

Board of Kopran recommends final dividend

Kopran announced that the Board of Directors of the Company at its meeting held on 15 May ...

Read more

15 May 2025 16:01

News

Kopran to hold board meeting

Kopran will hold a meeting of the Board of Directors of the Company on 15 May 2025. Powere...

Read more

07 May 2025 14:37

News

Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly

The United States Food and Drug Administration (USFDA) recently carried out a surveillance...

Read more

28 Apr 2025 15:03

News

Kopran to declare Quarterly Results

Kopran will hold a meeting of the Board of Directors of the Company on 11 February 2025. P...

Read more

05 Feb 2025 12:53

News

Kopran allots 36,200 equity shares under ESOP

Kopran has allotted 36,200 equity shares under ESOP on 21 January 2025. With this allotmen...

Read more

21 Jan 2025 18:36

News

Kopran to discuss results

Kopran will hold a meeting of the Board of Directors of the Company on 13 November 2024 Po...

Read more

06 Nov 2024 14:37

Venmax Drugs & Pharmaceuticals Ltd News Hub

News

Venmax Drugs & Pharmaceuticals to declare Quarterly Results

Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Compan...

Read more

16 Jul 2025 17:26

News

Venmax Drugs & Pharmaceuticals to table results

Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Compan...

Read more

02 May 2025 13:38

News

Venmax Drugs & Pharmaceuticals announces board meeting date

Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Compan...

Read more

04 Feb 2025 16:35

News

Venmax Drugs & Pharmaceuticals to conduct EGM

Venmax Drugs & Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of t...

Read more

13 Jan 2025 11:36

News

Venmax Drugs & Pharmaceuticals announces board meeting date

Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Compan...

Read more

07 Jan 2025 10:08

News

Venmax Drugs & Pharmaceuticals to table results

Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Compan...

Read more

31 Oct 2024 12:06

SWOT Analysis Of Venmax Drugs & Pharmaceuticals Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Kopran Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Venmax Drugs & Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Kopran Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Kopran Ltd and Venmax Drugs & Pharmaceuticals Ltd

Which company has a larger market capitalization, Kopran Ltd or Venmax Drugs & Pharmaceuticals Ltd?

Market cap of Kopran Ltd is 873 Cr while Market cap of Venmax Drugs & Pharmaceuticals Ltd is 13 Cr

What are the key factors driving the stock performance of Kopran Ltd and Venmax Drugs & Pharmaceuticals Ltd?

The stock performance of Kopran Ltd and Venmax Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kopran Ltd and Venmax Drugs & Pharmaceuticals Ltd?

As of July 18, 2025, the Kopran Ltd stock price is INR ₹180.8. On the other hand, Venmax Drugs & Pharmaceuticals Ltd stock price is INR ₹25.8.

How do dividend payouts of Kopran Ltd and Venmax Drugs & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Kopran Ltd and Venmax Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions